Genetic analysis of the M2/ANXA5 haplotype as recurrent pregnancy loss predisposition in the Malay population
- 151 Downloads
The aim of this study was to evaluate a new predisposition factor, M2/ANXA5 (RPRGL3), in recurrent pregnancy loss (RPL) patients of Malay origin, since it was previously known that the prevalence of this condition is relatively high among the Malay population of Malaysia, where conventional hereditary thrombophilia factors have been generally ruled out.
A total of 232 women who had experienced ≥2 unexplained RPL and 141 available male partners were recruited, with 360 healthy Malay and 166 parous female controls. Prevalence of M2 carriage and RPL odds ratios were calculated in (a) control and patient groups; (b) clinically defined subgroups in categories of pregnancy loss, primary, secondary, and tertiary; and (c) timing of pregnancy loss in early, ≤15th gestation week and “late” fetal losses, and >15th gestation week subgroups.
Both male and female subjects had similar M2/ANXA5 allele frequencies. The carrier rate of M2/ANXA5 for the general Malay population was 42.2 and 34.9% for parous controls. These carrier rates compared to Malay RPL subjects (52% M2 carriers) resulted in elevated odds ratios (95% confidence interval) of 1.53 (1.1 to 2.1) and 1.97 (1.3 to 3.1) accordingly for early fetal losses. Moreover, exceeding copy numbers of M2/ANXA5 alleles seemed to afflict a greater chance of RPL in couples, especially when both partners were M2 carriers.
This study confirmed the proposed role of M2/ANXA5 as embryonic, genetically associated thrombophilia predisposition factor for early RPL among ethnic Malay of Malaysia.
KeywordsAnnexin A5 M2/ANXA5 Recurrent pregnancy loss (RPL) Miscarriage
The authors thank the women and their partners who participated in this study.
Compliance with ethical standards
The present genetic association study was approved by the Human Ethics Research Committee of the Universiti Sains Malaysia (USMKK/PPP/JEPeM [245.3.(2)]) and from the National Institutes of Health, Ministry of Health, Malaysia (NMRR-11-1044-9519). The study was carried out in accordance with The Code of Ethics of the World Health Organization (Declaration of Helsinki), and the criteria of strengthening the reporting of genetic association studies were observed as far as applicable. The volunteer subjects who agreed to participate have signed an informed consent before collection of peripheral blood samples. Random Malay population subjects were recruited at the Universiti Sains Malaysia, Penang campus from January 2011 to May 2013 with appropriate informed consent.
This work was supported by Universiti Sains Malaysia Research Universiti Grant (USM RU grant no: 1001/CIPPT/812100) awarded to TTH. AM was funded by a PI grant of the German Research Community, DFG, MA-6288/1-1. AKC was supported by MyBrain15 Program (KPM (b) 850304015158) under the Malaysian Ministry of Education.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 10.Arshat H, Tan Boon A, Tey Nai P. The effects of life cycle and family formation variables on pregnancy outcome. Malaysian journal of reproductive health: a publication of the Reproductive Research Centre of the National Population and Family Development Board, Malaysia. 1985;3:115–25Google Scholar
- 15.Rand JH, Wu X-X, Quinn AS, Chen PP, McCrae KR, Bovill EG, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163:1193–200.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.The Rotterdam Eshre/Asrm-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.Google Scholar
- 27.Carp H, editor. Recurrent pregnancy loss: causes, controversies and treatment. London: CRC Press; 2007.Google Scholar
- 32.Irwan NM. Prevalence and risk factors of pregnancy loss in Malaysia. 2nd International Conference on Demography and Population Studies, 2015; Athens, Greece.Google Scholar
- 35.Rogenhofer N, Markoff A, Wagner A, Klein HG, Petroff D, Schleussner E, et al. Lessons from the EThIGII trial: proper putative benefit assessment of low-molecular-weight heparin treatment in M2/ANXA5 haplotype carriers. Clinical and Applied Thrombosis/Hemostasis. 2016.Google Scholar
- 36.Fishel S, Baker D, Elson J, Ragunath M, Atkinson G, Shaker A, et al. Precision medicine in assisted conception: a multicenter observational treatment cohort study of the annexin A5 M2 haplotype as a biomarker for antithrombotic treatment to improve pregnancy outcome. EBioMedicine. 2016;10:298–304.CrossRefPubMedPubMedCentralGoogle Scholar